Siemens gets FDA clearance for high-sensitivity troponin assays

Red blood cells
Troponin is released after the blockage of blood flow to the heart, indicating muscle damage. (Wikimedia Commons)

Siemens Healthineers received FDA clearance for two high-sensitivity troponin assays, which measure levels of the protein released into the bloodstream during a heart attack. They will now be made available in the U.S.

The company said the assays can detect lower levels of troponin in serum or plasma compared to traditional assays, with improved precision at the 99th percentile, as well as detect smaller changes in patients’ levels over time.

RELATED: Trinity Biotech yanks FDA submission for point-of-care heart failure test

The MedTech Conference

The MedTech Conference: September 23-25, Boston, MA

With over 3,000 attendees from 35 countries, The MedTech Conference features world-class plenary speakers, cross-cutting educational programming and business development opportunities. This is a prime opportunity to network, conduct business and share insights with medtech leaders. Register before July 26th and save $200!

The troponin I assays were cleared for use with the Siemens Healthineers’ Atellica IM and ADVIA Centaur XP/XPT in vitro laboratory analyzers. Siemens Healthineers is the separately managed healthcare business of Siemens AG.

Complaints of chest pain cause more than 8 million emergency room visits per year, the company said, though only about 5 percent end up being related to myocardial infarctions.

RELATED: Heart attack biomarker could ease ER crowding

Within 60 minutes of a heart attack, the presence of troponin in the bloodstream specifically indicates damage to the heart muscle. By measuring slight changes over time, ER physicians can more effectively triage life-threatening conditions and assign treatments or rule out and discharge patients who do not need to be in the hospital.

The assays have been available in Europe since May 2017, and meet current European Society of Cardiology guideline recommendations, the company said at the time.

Suggested Articles

Prenatal blood test developer Cradle Genomics has secured $17.1 million to help build out its laboratory operations.

CVS has begun to test out its at-home dialysis device designed to provide more frequent and thorough treatments compared to those in the clinic.

Eisai showed correlations between amyloid biomarkers in the blood and cerebrospinal fluid, bringing it closer to a simple blood test for Alzheimer’s.